In contrast to genetic mutations, epigenetic changes are potentially reversible, making them an attractive target for cancer treatment. Inhibitors directed against DNA methyltransferases and histone deacetylases-DNMTi and HDACi, respectively-are used for the treatment of several hematopoietic malignancies 1, 2 . Although these compounds have been in clinical use for several years, there is still a lack of knowledge regarding their mode of action 3 . Two previous studies on DNMTi in cancer cell lines reported the upregulation of double-stranded RNA (dsRNA) molecules, originating from codogenic endogenous retroviruses (ERV), followed by an interferon response and the induction of viral defense genes 4, 5 . However, it remains unclear how other classes of epigenetic drugs integrate into these findings and whether there are additional effects potentially missed by candidate gene approaches. Here, we globally mapped DNMTi-and HDACi-induced transcriptomic and epigenomic changes by using whole-genome profiling technologies ( Supplementary Fig. 1 and Supplementary Table 1 ) and show that the vast majority of TSSs that transcriptionally responded toward epigenetic modulation were cryptic, currently non-annotated TSSs encoded in solitary long-terminal repeats (LTRs).
RESULTS

Epigenetic drugs activate cryptic TSSs in the DAPK1 gene
To efficiently measure the effects of epigenetic drugs on endogenous gene expression, we engineered the lung cancer cell line NCI-H1299 by introducing a dual fluorescence/resistance reporter (EGFP-NEO) into intron 3 of DAPK1, which is epigenetically silenced in association with CpG-island hypermethylation ( Fig. 1a and Supplementary  Fig. 2a,b) . Upon treatment with the DNMTi 5-aza-2′-deoxycytidine (DAC) or with siRNAs or shRNAs targeting DNMT1 mRNA, the DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats DAPK1 promoter loses methylation, and a fusion transcript consisting of exons 1-3 and the EGFP-NEO reporter is expressed ( Supplementary Fig. 2c-f) . Consequently, DAPK1-reactivated cells can be further enriched and quantified by G418 selection (for NEO) or FACS sorting (for EGFP) (Fig. 1b) . To determine the suitability of this cell line to screen for epigenetically active substances, we tested several compounds that are known to affect various epigenetic enzyme classes. Epigenetic reactivation was read out in a G418-resistance screen in which cell viability increased mainly following treatments with DNMTi and HDACi ( Fig. 1c and Supplementary Fig. 2g ). We confirmed reporter gene expression after DNMTi or HDACi treatment by qRT-PCR (Fig. 1d, left) . To our surprise, the canonical DAPK1 mRNA was induced only upon DAC treatment but not after HDACi treatment (Fig. 1d, right) . We hypothesized that HDACi activates alternative TSSs located upstream of the EGFP-NEO sequence, thus giving rise to a truncated transcript lacking the 5′ region of the DAPK1 mRNA. By performing 5′ rapid amplification of cDNA ends (5′ RACE) on RNA extracted from treated cells, we identified three distinct transcript isoforms originating from cryptic (currently nonannotated) TSSs located within DAPK1 intron 2 (TSSs α, β, and γ), all of which were spliced into DAPK1 exon 3 ( Fig. 1e and Supplementary  Fig. 2h ). These transcripts contain novel sequences toward their 5′ ends (α, β, or γ) in place of the canonical first two exons that harbor the regular DAPK1 start codon, and they thus comprise alternative ORFs. We confirmed the existence of these transcripts by qRT-PCR (Fig. 1f) . In response to DNMTi and HDACi, the γ transcript was also found in wild-type NCI-H1299 cells, as well as in various other cancer cell lines (Fig. 1g) , indicating that its activation is neither cell line specific nor a consequence of genomic editing.
Global transcription from cryptic TSSs after treatment
We hypothesized that the aberrant activation of cryptic TSSs is not restricted to the DAPK1 locus but is a global phenomenon following treatment with epigenetic drugs. By using cap analysis of gene expression (CAGE), we mapped the genome-wide TSS usage of NCI-H1299 reporter cells treated with DNMTi (DAC), HDACi (SAHA or SB939), or both DAC and SB939 (DAC+SB) (Supplementary Data 1) . CAGE overcomes technical bottlenecks associated with standard RNA-seq, such as low coverage of transcript 5′ ends and difficulties in distinguishing multiple isoforms and splice variants that often overlap with reference transcripts. As a proof of concept, the CAGE data recapitulated our previous observations in that only DAC treatment, and not HDACi alone, reactivated the canonical DAPK1 TSSs (Fig. 2a,  left) . Moreover, we found several CAGE tags that supported the induction of the DAPK1 γ transcript and its respective splicing into exon 3 after treatment (Fig. 2a, right) .
Globally, epigenetic treatment substantially changed the TSS usage of cells, with the combinatorial treatment (DAC+SB) showing the strongest effects ( Fig. 2b and Supplementary Fig. 3a) . We performed differential TSS expression analysis using a fourfold expression change and a false discovery rate (FDR) <0.05 as minimal thresholds for differential expression. Epigenetic treatment caused both quantitative and qualitative expression changes at annotated TSSs (Fig. 2c, left) . In line with previous reports, DAC or DAC+SB treatment significantly upregulated cancer testis antigens (CTAs) as well as Aza-induced immune and viral defense genes (AIMs) 6 , which was accompanied by transcription from codogenic ERVs that have the capability to form dsRNAs and trigger an interferon response ( Supplementary  Fig. 3b-d) . It is important to note that neither SB939 nor SAHA significantly induced AIM expression, suggesting that HDACi exert their function independently.
However, we observed that all investigated drug regimens predominantly induced de novo transcription from currently non-annotated TSSs, termed here as treatment-induced non-annotated TSSs (TINATs) (Fig. 2c, right) . Although DNMTi and HDACi target distinct epigenetic pathways, inhibitor treatment mostly converged on the activation of identical TINATs (Fisher's exact test, P < 2.2 × 10 −16 ) (Fig. 2d, top) . + G418  selection   10   4   10   3   10   2   10   1   10   0   10  0 10  1 10  2 10  3 10  0 10  1 10  2 10  3 10  0 10  1 10  2 Moreover, TSS activity after SAHA and SB939 treatment was highly similar (r = 0.99) (Fig. 2d , bottom, and Supplementary Fig. 3e, right) . Thus, we focused on SB939 as a representative of HDACi for further analyses. In line with previous findings of the synergistic effect on gene expression by combined demethylation and HDACi 7 , we found multiple TINATs exclusively expressed after DAC+SB treatment. Moreover, the level of expression after combinatorial treatment was stronger than expected for the additive effect of DNMTi and HDACi alone (Fig. 2e) . This synergistic effect was significantly stronger at TINATs (median synergy score = 23.2) than at the TSSs of de novo-induced annotated genes (median = 3.5) or tumor suppressor genes (TSGs, median = 1.1) (Wilcoxon and Mann-Whitney two-sided test, P < 2.2 × 10 −16 ; Fig. 2f ).
The majority of TINATs were located in either intergenic (~60%) or intronic (~20%) regions ( Fig. 2g and Supplementary Fig. 4 ) with a median distance to the nearest annotated TSS of 9.3, 9.0, and 11.6 kb for DAC, SB939, and DAC+SB, respectively. Genes in the vicinity of DAC-induced TINATs were neither enriched for any biological process nor influenced by TINAT expression (correlation between TINAT expression and expression of nearby genes, r = 0). In contrast, genes most proximal to SB939-or DAC+SB-induced TINATs were enriched for neuronal and developmental processes ( Supplementary Fig. 3f ), and TINAT expression was positively correlated with the expression of nearby genes (SB939, r = 0.4 (P = 2.2 × 10 −9 ); DAC+SB, r = 0.21 (P = 3.9 × 10 −29 ); Supplementary Fig. 3g ). However, unlike active enhancer sites that are transcribed bidirectionally 8 , TINATs displayed unidirectional transcription (Supplementary Fig. 3h ).
As an example, Figure 2h depicts expression of two TINATs located in the introns of FBP2 and FANCC. We further confirmed the treatment specificity of TINATs by analyzing their expression across the FANTOM5 expression atlas 8 . The transcripts were generally not expressed under physiologic conditions, with the notable exception of testicular and fetal thymic tissues, which concurrently expressed up to ~40% and ~20% of all TINATs, respectively ( Fig. 2i and Supplementary Fig. 3i ).
TINAT-exon fusion transcripts encode aberrant proteins
Based on our initial observations at the DAPK1 locus, we analyzed whether TINATs generally spliced into genic exons. Approximately 50-60% of all TINATs generated spliced transcripts, of which another ~30% were spliced into protein-coding exons (Fig. 3a) . These observations are exemplified at the FBP2 locus, where TINAT-proximal splice sites join the cryptic TSS, with exon 2 located downstream of the canonical FBP2 translation start site (Fig. 3b) . We confirmed the existence of 15 TINAT-exon fusion transcript candidates in different cell lines by qPCR (Fig. 3c) . Fusion candidates were manually selected based on their expression level and the number of CAGE tags supporting the splicing event. Using StringTie 9 , we reconstructed 453, 744, and 3,627 TINAT-exon transcript isoforms for DAC-, SB939-, and DAC+SB-treated cells, respectively (Supplementary Table 2 and Supplementary Data 2). The exon-intron structure of the reconstructed transcripts closely matched the annotation of reference genes, as illustrated for FBP2. However, they often lacked the 3′ end of the canonical mRNA, because CAGE-tag density is strongly skewed toward the 5′ end and TSS of a transcript. Around 14-21% of TINAT transcripts overlapped protein-coding genes, and around 33-40% overlapped with long noncoding RNAs (lncRNAs) 10 . Although lncRNAs initiating from TINATs included transcripts with known function in disease, such as SCHLAP1 (ref. 11), we focused our further analyses on the protein-coding potential of TINATs. Most of the assembled fusion transcripts that contain a cryptic sequence at their 5′ end and a native protein-coding exon sequence downstream were predicted to be coding transcripts (Fig. 3d) . In silico translation showed that about half of the candidates encode in-frame isoforms relative to the coding DNA sequence of the canonical mRNA, whereas the other half generates outof-frame, and thereby completely novel, peptide sequences (Fig. 3e) . Fusion transcripts that are translated in-frame with the native coding DNA sequences give rise to either the original, truncated, or chimeric isoforms, depending on whether the canonical or variant in-frame start codons are used. The truncated isoforms often lacked domains or peptide sequences important for proper protein function, localization, or binding, whereas other functional regions remained unaffected (Fig. 3f) . TINAT fusion transcripts encoding the canonical full-length sequence comprised genes with products of diverse biological functions, including those for transcription factors (TFEC, TBX4, GTF2H5), DNA damage repair and apoptosis (RAD50, SESN1, TNFRSF10B), epigenetic modifiers (HDAC4), and CTAs (MAGEB10, BRDT). Several other CTAs were expressed from TINATs (PRSS55, MAGEB2, and XAGE5), but the resulting fusion transcripts were predicted 1  2  3  4  5  6  7  8  9  10  11  12  13  14   1  2  3  4  5  6  7  8  9  10  11  12  13  14  1  2  3  4  5  6  7  8  9  10  11  12  13  14  1  2  3  4  5  6  7  8  9  10  11  12  13  14  1  2  3  4  5  6  7  8  9  10  11  12  13  14   1  2  3  4  5  6  7  8  9  10  11  12  13  14  1  2  3  4  5  6  7  8  9  10  11  12  13  14  1  2  3  4  5  6  7  8  9  10  11  12  13 A r t i c l e s to encode out-of-frame peptides. While these out-of-frame transcripts are likely subjected to nonsense-mediated decay, chimeric peptide sequences encoded in TINAT fusion transcripts are potentially immunogenic, based on their foreign sequence and their capability of being presented on MHC class I molecules ( Fig. 3g and Supplementary  Fig. 5a ). Furthermore, most of these transcripts were not expressed in the adult thymus and hence would not be expected to contribute to central tolerance. Notably, none of the potentially immunogenic peptides corresponded to known CTAs 12 .
To confirm the translational capacity of selected fusion transcripts, we translated the canonical CRYGC mRNA and three TINAT-exon transcripts (CRYGC (chimeric-truncated), BCAS1 (normal), and FBP2 (truncated)) in vitro. For all RNA templates, we observed translation products with the predicted sizes (Supplementary Fig. 5b) . We further compared polysomal association of 15 TINAT-exon fusion candidates in DAC+SB-treated cells incubated in the absence or presence of the translation inhibitor harringtonine, to deplete elongating ribosomes from mRNAs 13 (Supplementary Fig. 5c ). As a positive control, β-actin (ACTB) mRNA showed highest abundance in heavy polysome fractions and strongest release upon harringtonine treatment ( Fig. 3h ; others shown in Supplementary Fig. 5d ). In contrast, the lncRNA HOTAIR was barely associated with polysomes and did not respond to harringtonine. All candidates were more strongly associated with heavy polysomes than HOTAIR, and we observed a harringtonine shift for CRYGC, ATP6V1H (out-of-frame), BCAS1, and COL28A1 (truncated), indicating their active translation. FARS2 (chimerictruncated) and DNAH3 (truncated) displayed a weak shift across only some replicates, thus precluding confident confirmation of their translational capacity. Additional testing of 28 TINAT-exon fusion candidates along fewer polysomal fractions identified nine additional candidates that reacted to harringtonine treatment ( Supplementary  Fig. 5e ). Concurrently, polysome fractionation of untreated colorectal cancer cells 14 showed that sporadically expressed transcripts overlapping with TINAT coordinates are preferably associated with heavy polyribosomes (Supplementary Fig. 5f ). To test the impact of translated fusion transcripts on cellular fitness, we overexpressed 11 candidate ORFs (Supplementary Table 3 ) in NCI-H1299 reporter cells and measured cellular proliferation. Overexpression of CRYGC, ATP6V1H, and FARS2 resulted in decreased cell growth (Fig. 3i) , whereas overexpression of the other ORFs had no effect (data not shown). Together, these observations suggest that TINATs frequently splice into protein-coding exons to create fusion transcripts that become translated into aberration protein isoforms.
DNMTi and HDACi activate TINATs via distinct mechanisms
To investigate the epigenetic reprogramming accompanying TINAT activation, we generated genome-wide maps of DNA methylation and 15 histone modifications before and after treatment (Supplementary Table 1 ). As expected, DAC treatment reduced global DNA methylation levels (Fig. 4a) , whereas HDACi rapidly increased the acetylation of histone tails at various positions ( Fig. 4b and Supplementary Fig. 6 ).
In untreated NCI-H1299 reporter cells, TINATs were silenced in association with DNA methylation and H3K9me3 around their TSS (Fig. 4c) but not with H3K27me3 (Supplementary Fig. 7a ). Treatment with DAC or DAC+SB ubiquitously decreased DNA methylation, which was partially compensated by increased levels of H3K9me3 (Fig. 4c) . Loss in DNA methylation was accompanied by an active promoter signature around TINATs, as suggested by the presence of various active histone modifications ( Fig. 4c and Supplementary  Fig. 7a) . In stark contrast to DAC or DAC+SB treatment, SB939 or SAHA treatment alone did not induce a classical promoter signature around TINATs, as indicated by the lack of demethylation and H3K4me3, H3K9ac, or H3K27ac histone marks ( Fig. 4c and  Supplementary Fig. 7b) . Rather, SB939 induced TINATs in association with H3K14ac, H2AK9ac, and H3K23ac ( Fig. 4c and Supplementary  Fig. 7a ). Although these marks were centered on TINATs, their signal intensity was low, potentially reflecting that only a small fraction of cells or alleles in the population responded to HDACi. Of note, most activating histone modifications displayed the strongest mean signal around TINATs after DAC+SB treatment, and some modifications, such as H2BK5ac and H3K4ac, were exclusively found after combinatorial inhibition, thereby providing a potential foundation for the synergistic effects of DAC+SB treatment on TINAT expression.
To gain further insights into the interplay of chromatin modulation and TINAT expression, we clustered TINATs based on their surrounding DNA methylation and histone modification profiles. We identified three distinct clusters (Supplementary Fig. 7c ) that differed in their respective epigenetic makeup (Fig. 4d and Supplementary Fig. 7d) . Cluster 1 was devoid of any of the investigated chromatin modifications in the vicinity of TINATs and was characterized by relatively low TINAT expression. TINATs of the second cluster harbored the most focal chromatin modifications that were strongly enriched in proximity to the TSS. Cluster 3 TINATs had lower levels of repressive DNA methylation and H3K9me3 than TINATs of cluster 2 and more widely distributed active chromatin marks after treatment. This chromatin signature was associated with the highest TINAT expression among the clusters. Together, these findings suggest that DNMTi and HDACi drive TINAT expression via distinct mechanisms, and that TINATs are associated with a heterogeneous group of TSS classes.
TINATs arise from LTRs of the LTR12 family
Although DNMTi and HDACi target different epigenetic pathways and are observed to employ different mechanisms of TINAT activation, both inhibitor classes converge on activating identical TINATs. We therefore hypothesized that these regions harbor some universal sequence commonality. Since it has been shown that transposable elements (TEs) play significant roles in regulating gene networks through novel promoter, enhancer, and splicing mechanisms 15, 16 , we explored whether sequence-specific features of TEs explain TINAT activation.
Indeed, more than 80% of TINATs overlapped with TEs (Fig. 5a) , and, specifically, the LTR class was more frequently associated with TINATs than expected by chance (Fig. 5b, top) . Following combination treatment, expression levels from LTR-derived TINATs were higher than from other TINATs (Supplementary Fig. 8a) . LTRs belonging to the LTR12 family, whose members are more frequently found at the promoter-TSS of genes than are other LTRs (Fisher's exact test, P < 2.2 × 10 −16 ; Supplementary Fig. 8b ), were strongly enriched for TINATs (Fig. 5b, bottom) . Moreover, certain TE families were enriched for the different chromatin clusters identified previously (Supplementary Fig. 8c ), suggesting that different epigenetic mechanisms are preferred for activation of certain TE families. Within the LTR12 family, LTR12C had the highest enrichment value (associated with ~50% of all TINATs, Supplementary Fig. 8d and Supplementary Table 4) . Analysis of public RNA-seq data from cells treated with SAHA 17 confirmed the selective transcriptional activation of LTR12C copies after HDACi (Supplementary Fig. 8e) . Moreover, we observed increased LTR12C transcription after SAHA treatment in a neuroblastoma mouse xenograft model (Wilcoxon and Mann-Whitney two-sided test, P = 0.0079; Fig. 5c ). Treatment with several chemotherapeutic agents did not affect LTR12C transcript levels (Supplementary Fig. 8f ), suggesting that their induction is a specific effect of epigenetic modulation. Next, we anchored the startpositions from TINATs to the LTR12C consensus sequence to identify if any sequence-specific context in LTR12C was contributing to the generation of TINATs (Supplementary Fig. 8g ). This analysis uncovered two intriguing results. First, all TSS activity originated from the second half of the sense strand, suggesting that LTR12C encodes unidirectional transcriptional regulation, similar to promoter function. Second, there was one major summit around position 1,165 bp that was activated synergistically by combination treatment, which corresponded to the previously identified ERV9 provirus TSS [18] [19] [20] . The broad range of CAGE peaks in LTR12C corresponds to the promoter region of the solitary LTR, thus supporting the notion that TINATs derive from cryptic silenced promoters 21 . This observation is in line with the previously described cases of LTR12C copies that harbor promoter activity (Supplementary Table 5 ). We therefore predicted that promoter-specific histone modifications increase around expressed LTR12C copies when treated with epigenetic drugs. As expected, we observed a significant increase in H3K4me3 and H3K9ac around expressed LTR12C but not for LTR12C copies without TINATs after DAC+SB treatment (Supplementary Fig. 8h) . Next, we asked whether LTR12C elements harbor TF-binding sites that provide insight into master TFs that mediate de novo transcription and whether there are sequence features that discriminate transcribed and non-transcribed LTR12C elements. Multiple-sequence alignment comparison of TINAT-producing and non-TINAT LTR12C copies showed that the most prominent sequence feature that segregated both LTR12C groups mapped immediately upstream of the 1,165-bp TINAT summit (Fig. 5d) . The ERV9/LTR12 U3 enhancer and promoter region harbors several TF-binding sites, such as NF-Y, Sp1 and GATA2 21 . We explored whether the presence of these three TF motifs directly upstream of the LTR12C summit correlated with TINAT presence. TINAT expression correlated with the presence of a GATA2 motif (tetrachoric correlation coefficient (cc) = 0.72) and Sp1 motif (cc = 0.69) (Fig. 5e) . Then, we checked expression levels of the LTR12C promoter TFs after DAC+SB treatment to explore the potential mechanism for TINAT activation. Using CAGE signal as a surrogate for gene expression, we identified that only GATA2 had significantly higher expression (Student's t test, P = 0.03) in DAC+SB relative to DMSO (Fig. 5f) . These findings suggest GATA2 is likely the upstream TF responsible for TINAT activation. Indeed, using siRNAmediated knockdown, we validated the requirement of GATA2 for full TINAT activation (Fig. 5g and supplementary Fig. 8i ).
DISCUSSION
We show that DNMTi and HDACi do not predominantly alter the expression of canonical genes but induce the de novo transcription of LTRs of the LTR12 family. Previous efforts to understand the transcriptional response toward epigenetic therapy were largely based on gene expression microarrays and thus were limited to the quantification of known transcripts and lacked information about their TSSs 22, 23 . Our findings extend recent reports that demonstrated the presence of dsRNA molecules upon DNMTi 4,5 , originating from the bidirectional transcription of codogenic ERV envelope gene loci (for example, Syncytin-1 and env-Fc2). While we confirmed Syncytin-1 expression and the subsequent induction of AIMs 6 upon DNMTi treatment, our data has important new implications. First, we show that HDACi must exert their function independently. Second, the unidirectional transcription from up to thousands of solitary LTRs is an additional effect to the bidirectional transcription from full-length ERV copies following treatment. Therefore, we provide a novel mechanism for the action of different classes of epigenetic inhibitors.
With the exception of Syncytin-1 and a few other codogenic ERVs that produce functional proteins 24 , most ERV genes became nonfunctional through various evolutionary forces 25 . Most of the ~700,000 ERV copies within the human genome exist as solitary LTRs 26 . Unlike other ERVs, the ~5,500 LTRs of the ERV9 family (LTR12s) carry several tandem repeats containing multiple TF-binding sites 21, 27 . LTRs of this family have been shown to shape the transcriptomic landscape through enhancer-like and promoter-like mechanisms 28, 29 , which have been adopted for tissue-specific functions 18, 19 . Our data suggest that either the loss of DNA methylation or HDAC inhibition is sufficient to drive faint expression of LTR12C elements, but combinatorial inhibition is required for full activation. The loss in DNA methylation upon DNMT inhibition is global and also occurs at LTR12Cs and other subfamilies that do not show a transcriptional response. We therefore propose that the selectivity of LTR expression is conferred by the disruption of repressive chromatin structure followed by binding of TFs to the regulatory sequence of exposed LTR elements. In line with the reported recruitment of GATA2 to LTR12 elements 30 , we show that GATA2 is required for full LTR12C expression. The selectivity of HDACi toward the activation of LTR12 family elements was also reported for multiple other cancer types based on candidate gene approaches 31, 32 , indicating that this is a universal mechanism. However, non-epigenetic treatment examples of EVR9/LTR12 reactivation have been discovered in viralinduced tumors 20 and in primary T cells infected with HIV 33 .
Splicing of ERV-derived transcripts into their genomic vicinity has been observed during normal development 16 and in tumors 20, 34 . There are reports from studies in mice or human cancer cells in which an LTR element gives rise to a chimeric protein by means of being spliced to a protein-coding gene 34, 35 . In line with these reports, we show that the treatment-induced expression of LTRs generates numerous fusion transcripts that encode novel protein isoforms, often lacking N-terminal peptide sequences important for proper protein function. Given that truncated protein isoforms affect cellular function and contribute to human disease 36, 37 , one expects that the simultaneous expression of aberrant peptides partially accounts for the clinical efficacy of these drugs.
So far, there are two major limitations to epigenetic therapy that could potentially be overcome by combining it with immunotherapy 38 . First, efficacy of DNMTi in different tumor entities is still quite limited, and second, despite promising initial results in lung cancer 39 , no phase 3 randomized trial has yet demonstrated therapeutic synergism between DNMTi and HDACi. The combination of epigenetic inhibitors with immunotherapy raises the hope that epigenetic therapy will demonstrate an antineoplastic effect in common cancer entities. Indeed, in preclinical cancer models, treatment with DNMTi or HDACi sensitizes tumors to the effects of immune checkpoint inhibition 4, 40 . Moreover, combining DNMTi with allogeneic T-cell infusions in the treatment of relapsed AML patients 41 indicates a curative potential 42 . Our data provide an elegant explanation for this priming effect, as epigenetic therapy may induce the expression of LTR-derived immunogenic antigens presented on MHC class I molecules for recognition by cytolytic T cells. This would be of utmost importance for those cancer types with low mutational burden that respond poorly to immune therapy 43 . The mechanism described here likely synergizes with other effects of epigenetic therapy, including the inhibition of nonsense-mediated decay 44 , transcription of viral defense genes 4 , increased antigen processing and presentation 45 , re-expression of epigenetically silenced inflammatory chemokines 46 , and upregulation of CTAs 47 . Future proteomic approaches combined with T-cell cytotoxicity assays will further shed light on the interaction between epigenetic and immune therapy and the role of ERV-derived antigen presentation.
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